Results 51 to 60 of about 2,820 (114)

ELDERLY WOMAN WITH REVERSIBLE DEMENTIA: A CASE OF NEUROCRYPTOCOCCOSIS

Brazilian Journal of Infectious Diseases
Neurocryptococcosis may present atypically, entering the differential diagnosis of rapidly progressive dementias. We report the case of a 74-year-old female patient with a prior diagnosis of rheumatoid arthritis on chronic methotrexate, with past use of ...
Gabriela Magalhães Grubert, Rafael Wagner Pereira, Gustavo de Araújo Pinto, Marcus de Luca Maciel, Sara Rizzatti Marques   +4 more
doaj   +1 more source

Induction and Prolonged Induction With Mirikizumab in Ulcerative Colitis—A Prospective, Real‐World Study From the Sicilian Network for Inflammatory Bowel Disease (SN‐IBD)

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background Mirikizumab (MIRI), an IgG4 monoclonal antibody targeting IL‐23 p19, was recently licensed for ulcerative colitis (UC). Most available data come from the pivotal trials, but real‐life data are scant. We aimed to evaluate the effectiveness and safety of MIRI in a real‐world setting.
Giuseppe Costantino, Anna Viola, Andrea Iuculano, Fabio Salvatore Macaluso, Raffaele Li Voti, Maria Cappello, Chiara Antoci, Concetta Ferracane, Morena Sciuto, Domenico Catarella, Stefanie Parisi, Filippo Mocciaro, Barbara Scrivo, Maria Emanuela Distefano, Roberto Vassallo, Maria Giovanna Minissale, Giuseppe Scalisi, Serena Garufi, Sofia Rao, Stefano Muscarella, Vincenza Tortorella, Emiliano Giangreco, Marco Muscianisi, Ambrogio Orlando, Walter Fries   +24 more
wiley   +1 more source

Toward Personalized Medicine in Type 1 Diabetes: Understanding How Patient Heterogeneity Influences Therapeutic Efficacy

Diabetes, Obesity and Metabolism, Volume 28, Issue 6, Page 4529-4545, June 2026.
ABSTRACT Pharmacologic interventions for type 1 diabetes (T1D) have advanced significantly in recent years with the advent of the first FDA approved therapy teplizumab for delaying symptomatic disease onset in 2022. Despite this progress, major hurdles remain in moving toward personalized medicine approaches for T1D.
Jasmine Pipella, Peter J. Thompson
wiley   +1 more source

Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 5, Page 1242-1250, May 2026.
Abstract Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real‐world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (≥ 2 to <18 years old)
Steven J. Steiner, Jeremy Adler, Shehzad A. Saeed, Richard S. Strauss, Kristin M. Howe, Anna Sheahan, Renping Zhang, Kimberly R. Keihn, Katharine Harrow, Kelly K. Olano, David A. Evans, Kim Hung Lo, Nanhua Zhang, Lilianne Kim, Richard B. Colletti, Sheri Volger, for the ImproveCareNow Learning Health Network, Sabina Ali, Rana Ammoury, Keren L. Appel, Travis Ayers, Howard Baron, Julie Bass, Rachel Bensen, Erica J. Brenner, José Cabrera, Mallory Chavannes, J Fernando del Rosario, Jill Dorsey, Dana M. H. Dykes, Dawn R. Ebach, Bhaskar Gurram, Dyer Heintz, Leslie M. Higuchi, Edward J. Hoffenberg, Jeannie S. Huang, Esther Jacobowitz Israel, Traci W. Jester, Ian Kang, Ian Leibowitz, Tiffany Linville, Ross M. Maltz, Craig A. McKinney, Lybil B. Mendoza Alvarez, Phillip Minar, Tina Morhardt, Alisa J Muñiz Crim, Barbara Joanna Niklinska‐Schirtz, Daniel M. O'Connell, Helen Pappa, Brad Pasternak, Trusha Patel, Meryl K. Perlman, Kelly C. Sandberg, Marc E. Schaefer, Robbyn E. Sockolow, David L. Suskind, Gitit Tomer, Jeanne Tung, Amanda A. Wenzel, Denise D. Young   +60 more
wiley   +1 more source

FRI0128 Integrated safety data analysis across phase 3 clinical studies for intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis [PDF]

Annals of the Rheumatic Diseases, 2018
Background Intravenous golimumab (IV GLM) is approved for treatment of adults w/rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Objectives To present the integrated safety data from three Phase 3 studies of IV GLM in patients (pts) w/RA, PsA and AS up to 24 weeks (wks).
M.E. Husni, S. Schwartzman, A. Deodhar, S. Kafka, S.D. Chakravarty, E.C. Hsia, D.D. Harrison, J.H. Leu, Y. Zhou, K.H. Lo, A. Kavanaugh   +10 more
openaire   +1 more source

No Increased Risk of Infection Following a Protocol Change to Decrease Duration of Perioperative Antibiotic Prophylaxis in Liver Transplantation

Transplant Infectious Disease, Volume 28, Issue 3, May/June 2026.
There was no increased rate of surgical site infection or bacteremia in liver transplant recipients following a decrease in perioperative antibiotic prophylaxis duration, with a change from 2.4% to 2.8% in patients hospitalized prior to transplant and 7.5% to 2.9% in other patients.
Hutton Brandon, Crystal M. Truax, Eduardo Rodriguez Zarate, Brandon J. Tritle, Hannah Imlay   +4 more
wiley   +1 more source

Transition From Juvenile Dermatomyositis to Spondyloarthritis: A Novel Overlapping Inflammatory Phenotype

ACR Open Rheumatology, Volume 8, Issue 3, March 2026.
Objective Juvenile dermatomyositis (JDM) is a rare childhood inflammatory myopathy, whereas spondyloarthritis (SpA) is an inflammatory arthropathy characterized by enthesitis and peripheral or axial involvement. We describe a series of patients diagnosed with JDM in childhood who later fulfilled classification criteria for SpA, a sequential phenotype ...
Austen Grooms, Ioannis Karageorgiou, Kerry Mychaliska, James Birmingham   +3 more
wiley   +1 more source

From Pharmaceutical to Biophysical Therapies: New Horizons in Inflammatory Bowel Disease Management

JCC Plus, Volume 1, Issue 2, March 2026.
Important limitations exist in the current pharmacological landscape of Inflammatory Bowel Disease (IBD), such as variable response rates and treatment‐limiting adverse effects. In this review, we perform a critical assessment of the current literature on novel multimodal biophysical approaches showing alternative mechanisms of action to, and potential
Benedetta Ricchi, Alejandra A. Carriles, Samuel Elias Pineda Chavez, Stefanos Bonovas, Arianna Dal Buono, Cristina Bezzio, Alessandro Armuzzi, Stefania Vetrano   +7 more
wiley   +1 more source

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1206-1209, June 2026.
Stephen J. Balevic, Daniel Gonzalez, Bernd Meibohm   +2 more
wiley   +1 more source

Reshaping study design for faster extrapolation‐based drug approval in pediatric inflammatory bowel diseases: An ESPGHAN–NASPGHAN position paper

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 3, Page 867-894, March 2026.
Abstract Children with inflammatory bowel diseases (IBD) have limited access to the available advanced therapies, given the lengthy gap between adult and pediatric approval. We aimed to review key hurdles for pediatric trials and recommend practical solutions.
Dan Turner, Amit Assa, Mikkel Malham, Shira Yuval Bar‐Asher, Carla Rayan, Jeffrey S. Hyams, Holm H. Uhlig, Brad Pasternak, David C. Wilson, Hilary K. Michel, Lissy de Ridder, Eric Zuckerman, Marina Aloi, Peter Szitanyi, Marla C. Dubinsky, Anne M. Griffiths, Roberto Saldana, Javier Martín‐de‐Carpi, Eytan Wine, Richard K. Russell, Jeremy Adler, Joseph Picoraro   +21 more
wiley   +1 more source